DJ-1 and alpha SYN in LRRK2 CSF do not correlate with striatal dopaminergic function

作者：Shi Min; Furay Amy R; Sossi Vesna; Aasly Jan O; Armaly Jeff; Wang Yu; Wszolek Zbigniew K; Uitti Ryan J; Hasegawa Kazuko; Yokoyama Teruo; Zabetian Cyrus P; Leverenz James B; Stoessl A Jon; Zhang Jing^*

来源：Neurobiology of Aging, 2012, 33(4): 836.e5.

DOI：10.1016/j.neurobiolaging.2011.09.015

• Parkinson's disease
• LRRK2
• Gene mutation
• Biomarker
• DJ-1
• alpha-synuclein

Previous studies demonstrated decreased levels of DJ-1 and alpha-synuclein (alpha SYN) in human cerebrospinal fluid (CSF) in patients with Parkinson's disease (PD), but neither marker correlated with PD severity, raising the possibility that they may be excellent progression markers during early or preclinical phases of PD. Individuals carrying the leucine-rich repeat kinase 2 (LRRK2) gene mutation are at increased risk for PD, and the phenotype of LRRK2 patients is almost identical to sporadic PD. To determine whether dopaminergic dysfunction in the basal ganglia, as determined by positron emission tomography (PET) scans, correlates with CSF levels of DJ-1 and alpha SYN during preclinical stages, Luminex assays were used to analyze CSF samples from asymptomatic LRRK2 mutation carriers, along with carriers who presented with a clinical diagnosis of PD. The data revealed no statistically significant relationship between PET scan evidence of loss of striatal dopaminergic function and the CSF biomarkers DJ-1 and alpha SYN, except for a weak correlation between DJ-1 and methylphenidate binding, suggesting that the use of these potential biomarkers on their own to screen LRRK2 gene mutation carriers for PD is not appropriate.

• 出版日期2012-4
• 单位华中科技大学